IP Library Granted Patent US 9,060,964
Granted Patent B2
US 9,060,964 · App. 13/789,216 · Granted Jun 23, 2015

Method of treating depression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,060,964
App. No.
13/789,216
Granted
Jun 23, 2015
Kind
B2
Abstract

Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.

Claims (18)

1. A method for treating depression in a subject, comprising administering to the subject a composition comprising about 5 to 60 unit equivalents of a botulinum toxin type A to one or more facial muscle in the subject, wherein the one or more facial muscle is a corrugator supercilii muscle, a procerus muscle, a frontalis muscle, an orbicularis oculi muscle, or a depressor anguli oris muscle; thereby treating depression in the subject.

2. The method of claim 1 , wherein the one or more facial muscle is an orbicularis oculi muscle, a frontalis muscle or a procerus muscle.

3. The method of claim 1 , wherein the one or more facial muscle is a corrugator supercilii muscle.

4. The method of claim 1 , wherein the one or more facial muscle is a depressor anguli oris muscle.

5. The method of claim 1 , further comprising administering an additional dose of about 30-50 Unit equivalents of the Botulinum toxin type A to the one or more facial muscle after about two to six months.

6. A method for treating dysthymia, major depression or a mood disorder in a subject, comprising:

administering a therapeutically effective amount of a composition comprising a botulinum toxin type A to one or more facial muscle to cause paralysis of the one or more facial muscle in the subject, wherein the one or more facial muscle is a corrugator supercilii muscle, a procerus muscle, a frontalis muscle, an orbicularis oculi muscle, or a depressor anguli oris muscle; wherein the therapeutically effective amount is an amount sufficient to cause paralysis of the one or more facial muscle;

thereby treating dysthymia, major depression or a mood disorder in the subject.

7. The method of claim 6 , wherein the one or more facial muscle is a depressor anguli oris muscle.

8. The method of claim 6 , wherein the one or more facial muscle is a frontalis muscle, an orbicularis oculi muscle, or a procerus muscle.

9. The method of claim 6 , wherein the one or more facial muscle is a corrugator supercilii muscle, or a procerus muscle.

10. The method of claim 6 , wherein the therapeutically effective amount is about 5-60 Unit equivalents of a Botulinum toxin type A.

11. The method of claim 10 , further comprising administering a second composition comprising an additional therapeutically effective amount of the Botulinum toxin type A to the one or more facial muscle after about two to six months.

12. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

13. The method of claim 12 , wherein the modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression.

14. The method of claim 12 , wherein the additional modality of treatment comprises a selective serotonin reuptake inhibitor.

15. The method of claim 6 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

16. The method of claim 15 , wherein the additional modality of treatment comprises a selective serotonin reuptake inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: FINZI, ERIC; ROSENTHAL, NORMAN E
To: MARYLAND MENTAL HEALTH INSTITUTE
Reel/Frame 050446/0153 →